A new guideline for the treatment of blood cholesterol was recently released by the American College of Cardiology (ACC) and the American Heart Association (AHA), serving as an update to the National Cholesterol Education Program’s (NCEP) Adult Treatment Panel III cholesterol guideline first released in 2001. With significant changes to key definitions, treatment strategy, and therapy selection, the guideline has transformed the treatment of blood cholesterol and also created controversy within the health care community. This controversy is largely focused on appropriate identification and treatment of patients for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Whereas statins play an integral role in the treatment and secondary prevention of ASCVD, their use for primary prevention is less clearly defined. It is imperative that health care providers are well versed in the concepts and controversies of the new guideline recommendations for primary prevention of ASCVD and can effectively assess the risks and benefits of statin therapy in this patient population.
StoneNJRobinsonJGLichtensteinAH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25, suppl 2):S1-S45. doi:10.1161/01.cir.0000437738.63853.7a.
2.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3143.
3.
PencinaMJNavar-BogganAMD’AgostinoRB. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422-1431. doi:10.1056/NEJMoa1315665.
4.
StoneNJRobinsonJGLichtensteinAH. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. Ann Intern Med. 2014;160:339-343. doi:10.7326/M14-0126.
5.
Cholesterol Treatment Trialists (CTT) Collaboration; BaigentCBlackwellLEmbersonJ. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
6.
StoneNJRobinsonJGLichtensteinAH. 2013Report on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease in adults: full panel report supplement. Circulation. 2013:1-396. doi:10.1161/01.cir.0000437738.63853.7a.
7.
ColhounHMBetteridgeDJDurringtonPN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
8.
NakamuraHArakawaKItakuraH. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-1163. doi:10.1016/S0140-6736(06)69472-5.
9.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622. doi:10.1001/jama.279.20.1615.
10.
RidkerPMDanielsonEFonsecaFAH. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-2207. doi:10.1056/NEJMoa0807646.
11.
Cholesterol Treatment Trialists (CTT) Collaboration; MihaylovaBEmbersonJBlackwellL. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
12.
Lloyd-JonesDMLeipEPLarsonMG. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798. doi:10.1161/CIRCULATIONAHA.105.548206.
13.
RoffiMAngiolilloDJKappeteinAP.Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32:2748-2757. doi:10.1093/eurheartj/ehr305.
14.
American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014;37(suppl 1):S14-S80. doi:10.2337/dc14-S014.
15.
GoffDCLloyd-JonesDMBennettG. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;63(25, pt B):2935-2959. doi:10.1161/01.cir.0000437741.48606.98.
16.
CannonCPBraunwaldEMcCabeCH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. doi:10.1056/NEJMoa040583.
17.
LaRosaJCGrundySMWatersDD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. doi:10.1056/NEJMoa050461.
18.
PedersenTRFaergemanOKasteleinJJP. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005;294:2437-2445. doi:10.1001/jama.294.19.2437.
19.
AminNPMartinSSBlahaMJNasirKBlumenthalRSMichosED. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA Risk Assessment Guidelines. J Am Coll Cardiol. 2014;63:2789-2794. doi:10.1016/j.jacc.2014.04.010.
20.
GottoAMMoonJE. Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. Nutr Metab Cardiovasc Dis. 2014;24:573-576. doi:10.1016/j.numecd.2014.04.002.
21.
RidkerPMCookNR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762-1765.
22.
WilkinsonMJLaffinLJDavidsonMH. Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014;28:439-452. doi:10.1016/j.beem.2014.01.006.
23.
JacobsonTA. NLA Task Force on Statin Safety: 2014 update. J Clin Lipidol. 2014;8(3):S1-S4. doi:10.1016/j.jacl.2014.03.003.
24.
MakiKCRidkerPMBrownWVGrundySMSattarN. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3, suppl):S17-S29. doi:10.1016/j.jacl.2014.02.012.
25.
PreissDSeshasaiSWelshP. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-2564. doi:10.1001/jama.2011.860.
26.
SattarNPreissDMurrayHM. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742.
27.
RichardsonKSchoenMFrenchB. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688-697. doi:10.7326/0003-4819-159-10-201311190-00007.
Rojas-FernandezCHGoldsteinLBLeveyAITaylorBABittnerV. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3, suppl):S5-S16. doi:10.1016/j.jacl.2014.02.013.
30.
TaylorFHuffmanMDMacedoAF. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev2013;1:CD004816.
31.
MillsEJRachlisBWuPDevereauxPJAroraPPerriD. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.
GuytonJRBaysHEGrundySMJacobsonTA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8:S72-S81. doi:10.1016/j.jacl.2014.03.002.
34.
RosensonRSBakerSKJacobsonTAKopeckySLParkerBA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58-S71. doi:10.1016/j.jacl.2014.03.004.
35.
HPS2-THRIVE Collaborative Group; LandrayMJHaynesRHopewellJC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212. doi:10.1056/NEJMoa1300955.
36.
AIM-HIGH Investigators, BodenWEProbstfieldJLAndersonT. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267. doi:10.1056/NEJMoa1107579.
37.
WierzbickiASViljoenA. Fibrates and niacin: is there a place for them in clinical practice?Expert Opin Pharmacother. 2014;15:2673-2680. doi:10.1517/14656566.2014.972365.
38.
CatapanoALFarnierMFoodyJM. Combination therapy in dyslipidemia: where are we now?Atherosclerosis. 2014;237:319-335. doi:10.1016/j.atherosclerosis.2014.09.026.
39.
ACCORD Study Group; GinsbergHNElamMBLovatoLC. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. doi:10.1056/NEJMoa1001282.
40.
GudzuneKAMonroeAKSharmaRRanasinghePDChelladuralYRobinsonKA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann Intern Med. 2014;160:468-476. doi:10.7326/M13-2526.
41.
BaigentCLandrayMJReithC. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.
42.
KasteleinJJPAkdimFStroesESG. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443. doi:10.1056/NEJMoa0800742.
43.
BlazingMAGiuglianoRPCannonCP. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168:205-212.e1. doi:10.1016/j.ahj.2014.05.004.
44.
BarnettJViljoenAWierzbickiA. The need for combination drug therapies in patients with complex dyslipidemia. Curr Cardiol Rep. 2013;15:1-7. doi:10.1007/s11886-013-0391-1.
45.
RossebøABPedersenTRBomanK. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356. doi:10.1056/NEJMoa0804602.
46.
LaRosaJCPedersenTRSomaratneRWassermanSM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am J Cardiol. 2013;111:1221-1229. doi:10.1016/j.amjcard.2012.12.052.
47.
SavareseGGottoAMJrPaolilloS. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090-2099. doi:10.1016/j.jacc.2013.07.069.
48.
PsatyBMAndersonMKronmalRA. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52:1639-1647. doi:10.1111/j.1532-5415.2004.52455.x.
49.
AnumEAAderaT. Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol. 2004;14:705-721. doi:10.1016/j.annepidem.2003.10.009.
50.
FellströmBCJardineAGSchmiederRE. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407. doi:10.1056/NEJMoa0810177.
51.
WannerCKraneVMärzW. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248. doi:10.1056/NEJMoa043545.
52.
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013;3:259-305.
53.
GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-1239. doi:10.1016/S0140-6736(08)61240-4.
54.
KjekshusJApetreiEBarriosV. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. doi:10.1056/NEJMoa0706201.
55.
JellingerPSSmithDAMehtaAEGandaO. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18(suppl 1):1-78.
